Spironolactone appears to be the front-runner for preferred fourth-line pharmacotherapy in patients with resistant hypertension. According to a review of the evidence, the mineralocorticoid receptor agonist is probably the best add-on therapy in patients with high blood pressure despite maximal doses of guideline-recommended triple therapy. Co-author Professor Markus Schlaich, head of the Dobney Hypertension Centre ...
Hypertension: theres more work to be done beyond triple therapy
By Mardi Chapman
9 Mar 2018